Rapid response on facial psoriasis to bimekizumab: case series
Psoriasis is a chronic inflammatory disease that can affect any part of the body but, when it appears in certain areas, like the face, it can have a very significant psychological impact. Biologics, in particular IL-17 and IL-23 drug inhibitors, have shown relevant clinical efficacy in the managemen...
Saved in:
Main Authors: | Nicoletta Bernardini (Author), Annunziata Dattola (Author), Giacomo Caldarola (Author), Diego Orsini (Author), Chiara Assorgi (Author), Alessandra D'Amore (Author), Giulia Maretti (Author), Antonio Giovanni Richetta (Author), Ersilia Tolino (Author), Nevena Skroza (Author), Concetta Potenza (Author) |
---|---|
Format: | Book |
Published: |
BioExcel Publishing Ltd,
2024-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of Cemiplimab in a Patient Affected by Cutaneous Squamous Cell Carcinoma and Myelodysplastic Syndrome
by: Ilaria Proietti, et al.
Published: (2023) -
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study)
by: Diego Orsini, et al.
Published: (2024) -
Eczematous eruption during bimekizumab treatment in a psoriatic patient previously treated with secukinumab
by: Gennaro Marco Falco, et al.
Published: (2024) -
Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient: a case report
by: Nicoletta Bernardini, et al.
Published: (2022) -
Long term efficacy, safety and tolerability of Tildrakizumab in epileptic patient with psoriasis and eczema
by: Nicoletta Bernardini, et al.
Published: (2022)